1 week Ago By ABMN Staff
Stock analysts at Craig Hallum began coverage on shares of Cardiff Oncology ( NASDAQ:CRDF – Get Free Report ) in a report issued on Friday, Marketbeat reports. The brokerage set a “buy” rating and a $8.00 price target on the stock.
Craig Hallum’s target price would indicate a potential upside of 279.15% from the stock’s current price. Cardiff Oncology Stock Performance Shares of Cardiff Oncology stock opened at $2.
11 on Friday. Cardiff Oncology has a 52-week low of $0.94 and a 52-week high of $6.
42. The company has a fifty day moving average of $2.29 and a 200-day moving average of $3.
29. The stock has a market capitalization of $98.22 million, a price-to-earnings ratio of -2.
34 and a beta of 1.95. Cardiff Oncology ( NASDAQ:CRDF – Get Free Report ) last posted its earnings results on Thursday, August 8th.
The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.
01). Cardiff Oncology had a negative return on equity of 62.65% and a negative net margin of 6,143.
91%. The firm had revenue of $0.16 million for the quarter, compared to analysts’ expectations of $0.
12 million. During the same quarter in the prior year, the company posted ($0.25) earnings per share.
On average, equities research analysts forecast that Cardiff Oncology will post -1 earnings per share for the current fiscal year. Institutional Investors Weigh In On Cardiff Oncology About Cardiff Oncology ( Get Free Report ) Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.
Recommended Stories Receive News & Ratings for Cardiff Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiff Oncology and related companies with MarketBeat.com's FREE daily email newsletter ..
